Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients
No Thumbnail
Authors
Nikolić-Vukosavljević, DragicaTodorović-Raković, N
Demajo, Miroslav
Ivanović, Vesna
Neskovic, B
Markicevic, M
Nešković-Konstantinović, Zora
Article
Metadata
Show full item recordAbstract
A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-posi...tive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.
Keywords:
ER/PR status / metastatic breast cancer / postmenopausal patients / survival / TGF-beta 1Source:
Clinical and Experimental Metastasis, 2004, 21, 7, 581-585Collections
Institution/Community
VinčaTY - JOUR AU - Nikolić-Vukosavljević, Dragica AU - Todorović-Raković, N AU - Demajo, Miroslav AU - Ivanović, Vesna AU - Neskovic, B AU - Markicevic, M AU - Nešković-Konstantinović, Zora PY - 2004 UR - https://vinar.vin.bg.ac.rs/handle/123456789/2869 AB - A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested. T2 - Clinical and Experimental Metastasis T1 - Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients VL - 21 IS - 7 SP - 581 EP - 585 UR - https://hdl.handle.net/21.15107/rcub_vinar_2869 ER -
@article{ author = "Nikolić-Vukosavljević, Dragica and Todorović-Raković, N and Demajo, Miroslav and Ivanović, Vesna and Neskovic, B and Markicevic, M and Nešković-Konstantinović, Zora", year = "2004", abstract = "A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.", journal = "Clinical and Experimental Metastasis", title = "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients", volume = "21", number = "7", pages = "581-585", url = "https://hdl.handle.net/21.15107/rcub_vinar_2869" }
Nikolić-Vukosavljević, D., Todorović-Raković, N., Demajo, M., Ivanović, V., Neskovic, B., Markicevic, M.,& Nešković-Konstantinović, Z.. (2004). Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis, 21(7), 581-585. https://hdl.handle.net/21.15107/rcub_vinar_2869
Nikolić-Vukosavljević D, Todorović-Raković N, Demajo M, Ivanović V, Neskovic B, Markicevic M, Nešković-Konstantinović Z. Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis. 2004;21(7):581-585. https://hdl.handle.net/21.15107/rcub_vinar_2869 .
Nikolić-Vukosavljević, Dragica, Todorović-Raković, N, Demajo, Miroslav, Ivanović, Vesna, Neskovic, B, Markicevic, M, Nešković-Konstantinović, Zora, "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients" in Clinical and Experimental Metastasis, 21, no. 7 (2004):581-585, https://hdl.handle.net/21.15107/rcub_vinar_2869 .